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CholinePhosphatidylethanolamine N-methyltransferase (PEMT) catalyzes the methylation of phosphatidylethanol-
amine to phosphatidylcholine (PC). This 22.3 kDa protein is localized to the endoplasmic reticulum and mito-
chondria associated membranes of liver. The supply of the substrates AdoMet and phosphatidylethanolamine,
and the product AdoHcy, can regulate the activity of PEMT. Estrogen has been identiﬁed as a positive activator,
and Sp1 as a negative regulator, of transcription of the PEMT gene. Targeted inactivation of the PEMT gene pro-
duced mice that had a mild phenotype when fed a chow diet. However, when Pemt−/− mice were fed a
choline-deﬁcient diet steatohepatitis and liver failure developed after 3 days. The steatohepatitis was due to a
decreased ratio of PC to phosphatidylethanolamine that caused leakage from the plasma membrane of hepato-
cytes. Pemt−/− mice exhibited attenuated secretion of very low-density lipoproteins and homocysteine.
Pemt−/− mice bred with mice that lacked the low-density lipoprotein receptor, or apolipoprotein E were
protected from high fat/high cholesterol-induced atherosclerosis. Surprisingly, Pemt−/− mice were protected
from high fat diet-induced obesity and insulin resistance compared to wildtype mice. If the diet were
supplemented with additional choline, the protection against obesity/insulin resistance in Pemt−/− mice was
eliminated. Humans with a Val-to-Met substitution in PEMT at residue 175 may have increased susceptibility
to nonalcoholic liver disease. This article is part of a Special Issue entitled Phospholipids and Phospholipid
Metabolism.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
PhosphatidylethanolamineN-methyltransferase (PEMT) catalyzes the
conversion of phosphatidylethanolamine (PE) to phosphatidylcholine
(PC) by the transfer of 3 methyl groups from S-adenosylmethionine to
PE. In 1941 it was demonstrated that methyl groups from methionine
couldbeutilized for the formationof choline [1]. In that sameyear, Stetten
demonstrated that [15N]ethanolamine was methylated to form choline
which was then converted into PC [2]. It was not until 1960 that Bremer
and Greenberg demonstrated that PE was the methyl group acceptor
[3,4]. Subsequently, they characterized PEMT activity on rat liver micro-
somes [5].Hcy, S-adenosylhomocysteine;
osahexaenoic acid; ER, endo-
eciﬁc CTα knockout; PC, phos-
T, phosphatidylethanolamine
density lipoproteins
ospholipids and Phospholipid
eritage Medical Research Cen-
G2S2. Tel.: +1 780 492 8286;
l rights reserved.2. Puriﬁcation and characterization of PEMT
PEMT is tightly associated with the membranes of the endoplasmic
reticulum (ER). Hence, attempts at puriﬁcation were plagued by pitfalls
and problems. Puriﬁcation of membranous enzymes has been charac-
terized as “masochistic enzymology” [6]. However, persistence and
dedication by N. Ridgway resulted in the puriﬁcation of a small protein
(22.3 kDa) from Triton X-100 solubilized rat liver microsomes [7]. The
pure protein catalyzed all 3 transmethylation reactions for the conver-
sion of PE to PC. It appeared that this protein accounted for all themeth-
ylation of PE that occurs in liver. However, this was not conclusively
demonstrated until the gene encoding PEMT was disrupted in mice
[8,9]. Pemt−/− mice had no residual activity in the conversion of PE to
PC [9].
The pure enzyme used PE, phosphatidyl-monomethylethanolamine
and phosphatidyl-dimethylethanolamine as substrates [10]. Kinetic
studies suggest a common substrate binding site for the 3 phospholipid
substrates [11]. The pHoptimum for all 3 reactions catalyzed by PEMT is
10.5 [12]. Since the pH of the cytoplasm in cells is usually 7.4, PEMT ac-
tivity would normally bewell below its potential. The physiological sig-
niﬁcance, if any, of the high pH optimum is not clear.
A crystallographic or NMR structure for PEMT has not yet been
reported. Topographical studies of the enzyme on the ER membrane
suggest that four transmembrane regions span the membrane such
that both the C-terminus and N-terminus face the cytosolic side of
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tiﬁed on the 3rd and 4th transmembrane sequences near the cytosolic
surface of the ER [14]. It is remarkable that such a small protein can
bind one of three phospholipid substrates as well as AdoMet. It will
be interesting to determine the structure of PEMT to show how this
small protein can bind these substrates.
Three novel forms of PEMTmRNAwere identiﬁed in human liver by
cloning of the cDNAs [15]. These forms differ from each other in the
5′-region with the point of divergence being 15 nucleotides upstream
of the codon for initiation of translation. Each of the 3 PEMT transcripts
was detected in human liver [16] whereas the heart expressed one of
the transcripts. The testis expressed the same transcript as the heart
as well as a small amount of another transcript. The three cDNAs were
ectopically expressed in human embryonic kidney (HEK)-293 cells.
One of the transcripts (designated as PEMT-L) had the N-terminal do-
main in the lumen of the ER and this domain was N-glycosylated with
mannose oligosaccharides [17]. The speciﬁc activity of PEMT-L was
much lower than that of the other two expressed transcripts (designat-
ed as PEMT-S). The PEMT-S forms were not glycosylated.
PEMT activity is highly expressed only in liver [18]. Nevertheless,
low activities have been found in other tissues (e.g., heart, adipocytes).
There is now evidence that PEMT activity might be important in lipid
droplet biosynthesis in adipocyte cells and white adipose tissue [19].
3. Cloning and expression of Pemt cDNA
The puriﬁcation of PEMT allowed us to obtain enough sequence of
the protein to permit cloning and expression of Pemt cDNA [20]. The
encoded protein contains 199 amino acids. An antibody was raised
against the carboxyl terminus of PEMT. Subcellular fractions of rat
liver were prepared, PEMT activity was measured and immunoblot-
ting of the protein was performed [20]. Whereas most of the activity
was found on the ER, there was no immunoreactivity with the anti-
body to PEMT on the ER. Rather, the antibody reacted with a protein
on mitochondrial-associated membranes (MAM) [21], a subfraction
of ER that associates with mitochondria. Subsequent attempts to dis-
tinguish the difference between PEMT on the ER and the MAM have
been unsuccessful.
4. Regulation of the conversion of PE to PC
In an earlier reviewwe summarized evidence that the supply of sub-
strates for PEMT, and one product, S-adenosylhomocysteine, were
major regulators of PEMT activity [18,22,23]. More recent studies have
focused on transcriptional regulation of the expression of PEMT. The
proximal promoter region for the PEMT gene does not contain a TATA
box preceding the transcriptional start site in mice or humans [8,16].
Potential transcription factor binding sites were identiﬁed for hepatic
nuclear factor, activating factor-1 (AP-1), and Sp1.
Estrogen was implicated as a positive regulator of PEMT transcrip-
tion in primary cultures of mouse and human hepatocytes [24]. How-
ever, it is not clear if the observed changes in PemtmRNA levels were
caused by increased mRNA stability or alterations in gene transcrip-
tion. Nevertheless, subsequent studies suggest that in some women
the estrogen binding site in the PEMT promoter region is ablated,
which has been proposed to put these women at risk for hepatic
steatosis due to choline deﬁciency syndrome [25]. Moreover,
pre-menopausal women are less likely to develop signs of muscle
and liver damage when fed a choline-deﬁcient diet, compared to
postmenopausal women and to men [26]. The observed estrogen reg-
ulation of PEMT expression is consistent with the report that female
mice have higher expression of PEMT than do male mice [27].
A major difﬁculty in studying the transcriptional regulation of
PEMT expression was identiﬁcation of a suitable cell line that
expressed PEMT. Even though primary hepatocytes express PEMT,
studies in these cells are difﬁcult because the expression of PEMTbegins to decline after culturing. Moreover, there is no suitable hep-
atoma cell line that shows signiﬁcant expression of PEMT. This prob-
lem was overcome when 3T3-L1 cells were shown to increase the
expression of PEMT during differentiation into adipocytes [28].
5′-Deletion analyses of PEMT promoter-luciferase constructs stably
expressed in 3T3-L1 cells implicated a regulatory region between
−471 and −371 bp relative to the transcription start site. This re-
gion of the proximal promoter contains a binding site for Sp1. During
the differentiation of 3T3-L1 cells into adipocytes, the level of Sp1 pro-
tein decreased just before the expression of PEMT increased. These
and other experiments directly implicate Sp1 as a negative regulator
of PEMT transcription [28]. In contrast, Sp1 is a positive regulator of
the expression of CTP:phosphocholine cytidylyltransferase (CT) the
rate-limiting enzyme of the CDP-choline pathway for PC synthesis
[29–32]. Moreover, the CDP-choline pathway is up-regulated in liver
when PEMT expression is decreased during hepatic regeneration and
growth [33–35]. Therefore, Sp1 may have an important role in the re-
ciprocal regulation of PEMT and CT.
5. Targeted deletion of the mouse Pemt gene
Until the technology was developed for speciﬁcally inactivating
genes in mice, approaches to understand the roles of speciﬁc genes
in mouse physiology were limited. Hence, it was of great interest to
inactivate the Pemt gene in mice. At the time this was a rather difﬁcult
assignment because we needed to obtain information on the struc-
ture of the PEMT gene so that we could generate targeting vectors.
Nevertheless, sequence of the Pemt gene in mice was established by
C. Walkey in 1996 [8] and subsequently the Pemt gene was disrupted
in mice [9]. The mice appeared overtly normal and the levels of PE
and PC were minimally affected by elimination of PEMT. The observa-
tion that PC levels were not affected is possibly due to a 60% increase
in activity of CT in the livers of the Pemt−/−mice (another example of
reciprocal expression of the PEMT and the CDP-choline pathways).
It was not too surprising that Pemt−/−mice did not exhibit an ob-
vious phenotype since the mice still had the more quantitatively sig-
niﬁcant CDP-choline pathway that is estimated to be responsible for
70% of the PC made in liver [22,36]. Thus, we stressed the Pemt−/−
mice by feeding them a choline-deﬁcient diet. A remarkable pheno-
type resulted and the mice developed severe liver failure (Fig. 2)
after 3 days, and would have died within the next 24–48 h had they
not been sacriﬁced [37]. The experiments suggested that the PEMT
pathway was selected during evolution to provide a distinct advan-
tage for animals during fasting/starvation. Under those conditions,
choline would not be ingested from the diet and the animal would
rely on PEMT to convert PE to PC that could be degraded as a source
of choline (see Section 8 for more on PEMT as a source of choline).
The rapidity of liver failure in Pemt−/− mice fed the choline-
deﬁcient diet was initially an enigma. A major pathway for utilization
of hepatic PC is the secretion of bile into the intestine. The liver of a
20 g mouse contains ~20 mg of PC and secretes ~23 mg of PC into
bile each day [38]. In 1993, Smit et al. disrupted the gene (Mdr2) re-
sponsible for transfer of PC into the bile [39]. Upon breeding the
Pemt−/− mice with Mdr2−/− mice, we generated mice in which both
genes were disrupted. Subsequently, we fed the double knock-out
mice a choline-deﬁcient diet. As expected the Pemt−/− mice showed
rapid liver failure in 3 days. In contrast, the Pemt−/−/Mdr2−/−mice sur-
vived for >90 days [40]. Thus, it appears that the acute lethality in
Pemt−/− mice fed the choline-deﬁcient diet is due to the rapid deple-
tion of hepatic PC via biliary PC secretion.
The Pemt−/− mice exhibited both steatosis and steatohepatitis
that led to liver failure when fed the choline-deﬁcient diet whereas
Pemt−/−/Mdr2−/− mice developed only severe steatosis [41]. The
liver failure was shown to be due to a loss of membrane integrity
due to a ratio of PC to PE that decreased below 1 (normal ratio is
~1.8). This abnormal PC/PE ratio in hepatocytes led to leakage of
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Fig. 1. Proposed orientation for PEMT in the membrane of the endoplasmic reticulum. N refers to amino terminal of the protein and C to the carboxyl terminal of PEMT.
This ﬁgure was kindly supplied by Dr. Joanne Lemieux and TuoHuang Zhang, University of Alberta.
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brane, and cell death. In contrast, the Pemt−/−/Mdr2−/− mice
maintained a near normal PC/PE ratio and cell membrane integrity
was maintained. The PC/PE ratio thus appears to be a key regulator
of cell membrane permeability and a disturbance in this ratio may
have an important role in the progression of steatosis into
steatohepatitis. In addition, the studies demonstrate that PEMT is an
important source of PC for hepatic membranes.
In subsequent studies we tested the hypothesis that PEMT was re-
quired for optimal secretion of bile from the livers of mice. However,
PC secretion into bile was not altered in Pemt−/− mice under normal
choline supplementation [42]. Hence, the CDP-choline pathway is
sufﬁcient for normal PC secretion into bile even when bile secretion
is stimulated by infusion of bile salts.
Pemt−/− mice are susceptible to hepatic steatosis and abnormally
low levels of cholinemetabolites in the liver when fed a normal amount
of choline in their drinking water (6.4 mmol/L) [43,44]. Nevertheless,
even when the choline content of the drinking water was increased to
29 mmol/L, the Pemt−/− mice still exhibited steatosis. Thus, it seems
that PEMT activity is quantitatively a very important source of choline.
In other studies, PEMT has been implicated as an important source of
PC species containing arachidonic acid and docosahexaenoic acid
(DHA) that are secreted into plasma [44]. In line with these ﬁndings,
brains from Pemt−/− mice at gestational day 17 contained 25–50%
less DHA in the phospholipids than did Pemt+/+mice [45]. Supplemen-
tation of the diet of Pemt−/− mice with DHA increased fetal brain
phospholipid-DHA to levels similar to those in Pemt+/+ mice. ClinicalPemt+/+ Pemt-/-
Fig. 2. Photo of livers from Pemt+/+ and Pemt−/−mice that consumed a choline deﬁcient
diet for 3 days. The gall bladder can be observed in the liver from the Pemt−/−mouse.studies have also implicated DHA content of plasma PC as a potential
marker of PEMT activity in humans [46].
6. PEMT, lipoprotein secretion and atherosclerosis
When very low density lipoproteins (VLDL) are secreted from the
liver they are enriched in PC compared to hepatocytes [47]. Studies in
the 1980s demonstrated that either choline or methionine was required
for normal secretion of VLDL from rat primary hepatocytes [48–50].
Whereas choline is a precursor of PC produced via the CDP-choline path-
way, methionine is converted to AdoMet that is themethyl donor for the
conversion of PE to PC via PEMT. Studies in mice in which CTα
(rate-limiting enzyme for PC biosynthesis via the CDP-choline pathway
[51])was eliminated speciﬁcally in the liver (hepatocytes) demonstrated
that the secretion of VLDL was decreased despite a 2-fold increase in the
expression of PEMT in these livers [52]. Similarly, hepatocytes frommice
that lacked PEMT had decreased secretion of VLDL compared to Pemt+/+
mice [53]. In partial agreementwith these observations, PEMT deﬁciency
decreased the hepatic secretion of VLDL inmale, but not female, Pemt−/−
mice [27]. Thus, it seems that both the CDP-choline and the PEMT path-
ways are required for optimal secretion of VLDL from livers ofmice.Why
one pathway cannot compensate for the other is not clear. Nor doweun-
derstand the mechanism underlying the gender-speciﬁc effects on the
secretion of VLDL from Pemt−/−mice.
The availability of Pemt−/− mice with decreased VLDL secretion
allowed us to address the question of whether or not Pemt−/− mice
were protected from atherosclerosis. C57Bl6 mice are resistant to
diet-induced atherosclerosis. Studies are, thus, often performed with
gene-targeted mice that are prone to this disease. Two commonly
used models are mice lacking LDL receptors (Ldlr−/−) that are fed a
high-fat, high-cholesterol diet, and chow-fed mice that lack apolipo-
protein E (Apoe−/−) [54]. We, therefore, cross bred the Pemt−/−
mice with mice having either of these two genetic backgrounds.
PEMT deﬁciency strikingly protected Ldlr−/−mice from atheroscle-
rosis. Compared to Pemt+/+/Ldlr−/− mice fed the high-fat, high-
cholesterol diet for 16 weeks, Pemt−/−/Ldlr−/− mice developed ~80%
fewer atherosclerotic lesions (Fig. 3) [55]. This ﬁnding was consistent
with the atheroprotective plasma lipoprotein proﬁle in which
VLDL/low density lipoprotein lipids were signiﬁcantly lower in the
Pemt−/−/Ldlr−/− mice (TG reduced by ~70%, cholesterol by ~56%,
phospholipid by ~45% and cholesteryl esters by ~69%) [55]. The
levels of plasma apo B100 and apo B48 were reduced by 30% and
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Ldlr−/− mice compared to Pemt+/+/Ldlr−/− mice consistent with
the decreased plasma lipid levels. In addition, the VLDL particles in
plasma of Pemt−/−/Ldlr−/−mice had a signiﬁcant 34% lower content
of PC than did VLDL in the plasma of Pemt+/+/Ldlr−/−mice [55]. The
in vivo clearance of VLDLs from Pemt−/−/Ldlr−/− mice was also
much more rapid than from Pemt+/+/Ldlr−/− mice, likely due to
the alteration in VLDL structure caused by decreased lipid content.
Thus, the protection from atherosclerosis observed in Pemt−/−/
Ldlr−/− mice compared to Pemt+/+/Ldlr−/−mice is due to impaired
PC biosynthesis in the liver that leads to diminished secretion of
PC-deﬁcient VLDL that is more rapidly cleared compared to VLDL
produced by Pemt+/+/Ldlr−/− mice.
PEMTdeﬁciency inApoe−/−mice fed a chowdiet for 1 year also pro-
vided protection from the development of atherosclerosis [56]. In this
study, cardiac function was also assessed. In vivo echocardiography
demonstrated a ~50% improvement in systolic function in the
Pemt−/−/Apoe−/− mice compared to Pemt+/+/Apoe−/− mice. In addi-
tion, there was a signiﬁcant 34% reduction in TG in the hearts of
Apoe−/−mice that lacked PEMT. Thus, our data suggest that disruption
of the Pemt gene decreases atherosclerosis and attenuates the develop-
ment of a lipotoxic cardiomyopathy in mice that lack apo E.7. The PEMT reaction is a major source of plasma homocysteine
Mild hyper-homocysteinemia is an independent risk factor for car-
diovascular and atherosclerotic diseases [57–59]. A 50% increase in plas-
ma homocysteine (Hcy) is linked to a 60% increase in risk of coronary
artery disease for men, and 80% increase for women. Hcy is a
non-protein amino acid that is a breakdown product of AdoHcy which
is generated by transmethylation reactions in which AoMet is themeth-
yl donor [57]. Hcy can be converted tomethionine or cysteine, or can be
secreted. A potential major source of Hcy is AdoHcy generated by the 3
successive methylation reactions catalyzed by PEMT during the conver-
sion of PE to PC. In studies with Pemt−/−mice, we showed that the plas-
ma levels of Hcy were decreased by 50% compared to those in Pemt+/+
mice [60]. Moreover, hepatocytes isolated from Pemt−/−mice secreted
50% less Hcy than did Pemt+/+ hepatocytes [60]. In companion experi-
ments, McArdle RH7777 hepatoma cells stably transfected with a
cDNA encoding PEMT resulted in an almost 3-fold higher amount ofFig. 3. Atherosclerosis in aortic root regions from Pemt+/+/LDLr−/−mice (top 3 panels) and fro
(light blue).Hcy in the medium after a 24 h incubation compared to hepatoma
cells transfected with vector alone [60].
To gain further insight into the physiological role of PEMT as a
modulator of plasma Hcy, we studied Hcy formation in mice that
lacked hepatic CTα (LCTαKO). In these mice, the activity of PEMT is
double that in mice that express CTα [52,61] and plasma Hcy was
20–40% higher in the LCTαKO mice [61]. Furthermore, hepatocytes
isolated from LCTαKO mice secreted 40% more Hcy than did control
hepatocytes. Thus, PEMT is not only important for producing PC in
the liver but is also a signiﬁcant source of plasma Hcy in mice.
There are at least 50 AdoMet-dependent methylation reactions in
mammals [62]. The biosynthesis of creatine has been estimated to uti-
lize ~70% of AdoMet in humans [63]. With the new information avail-
able on the quantitative signiﬁcance of the PEMT reaction in the
utilization of AdoMet, it is likely that the contribution of creatine bio-
synthesis to AdoMet utilization may be less than previously estimated
[64,65].8. No one predicted a relationship between PEMT, obesity and type
2 diabetes
Perhaps one of the most rewarding aspects of biomedical re-
search is that we expect the unexpected. An excellent example is
the discovery that mice that lack PEMT are strikingly protected
from high fat-induced obesity and insulin resistance [66]. When
the Norwegian Jon Bremer ﬁrst characterized PEMT activity in mi-
crosomes [5], a relationship between this membrane-bound en-
zyme and obesity would not have entered his mind. There were no
clues to this connection between PEMT and obesity until Pemt−/−
mice were fed a high-fat diet. Unlike Pemt+/+ mice that gained
10 g over 10 weeks when fed the high-fat diet, the PEMT-deﬁcient
mice held their weight constant at 30 g (Fig. 4) [66]. The Pemt−/−
mice were also protected against insulin resistance that developed
in the Pemt+/+ mice fed the high-fat diet, as reﬂected by their intol-
erance to glucose and insulin [66]. On the other hand, the Pemt−/−
mice developed steatosis (TG in livers from Pemt+/+ mice was
184 μg/mg protein compared to 790 μg/mg protein in Pemt−/−
mice). In the Pemt−/− mice, plasma alanine aminotransferase (a
marker for liver disease) was 10-fold higher than in Pemt+/+ mice
(7.2 units/L compared to 71.2 units/L).m Pemt−/−/LDLr−/−mice (bottom 3 panels). Stainedwith oil red O (red) and hematoxylin
KO
WT
Fig. 4. Photo of a Pemt+/+mouse (WT) and a Pemt−/−mouse (KO) that have been fed a
high fat diet for 10 weeks.
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tance (type 2 diabetes)? One explanation is that the Pemt−/−mice fed
the high fat diet are hypermetabolic, as reﬂected in their increased ox-
ygen consumption. Moreover, these mice rely more on glucose, than
fat, as a source of energy compared to Pemt+/+ mice [66].
We considered the possibility that the signiﬁcant decrease in hepatic
PC from76 nmol/mgprotein in Pemt+/+mice to 57 nmol/mgprotein in
Pemt−/− mice might lead to decreased obesity and increased insulin
sensitivity. Hence, we determined if the hepatic speciﬁc CTα knockout
(LCTαKO) mice were also protected from obesity/insulin resistance.
This seemed a reasonable hypothesis since the CT pathway accounts
for ~70% of hepatic PC biosynthesis [22,67]. However, compared to
ﬂoxed control mice, the LCTαKO mice gained a similar 10 g of weight
when fed the high fat diet for 10 weeks [66]; oxygen consumption
and glucose tolerance test were the same in the two strains of mice.
Thus, the amount of PC in the liver does not appear to be a factor in
protecting Pemt−/−mice from obesity/insulin resistance.
We have focused on the role of PEMT in PC production particularly
in the liver.What is generally not appreciated is that PC can be degraded
via phospholipases C/D to generate phosphocholine/choline [68]. Thus,
LCTαKO mice (that contain PEMT) can synthesize choline de novo
whereas Pemt−/−mice cannot. The high fat diet we have used contains
1.3 g of choline/kg diet. Hence, the mice are not choline-deﬁcient. But
perhaps the Pemt−/− mice were not choline sufﬁcient. Hence, we
supplemented the high-fat diet with an additional 2.7 g of choline/kg
diet and were astonished to ﬁnd that the beneﬁts of reduced obesity
and increased insulin sensitivity in Pemt−/− mice were abolished.
Thus, the Pemt−/− mice fed the high-fat/high-choline diet gained
weight, developed glucose intolerance and showed othermetabolic fea-
tures characterisitic of Pemt+/+mice fed the high-fat diet [66]. These re-
sults strongly imply that the deﬁciency of PC in the liver per se had not
provided the protection observed in Pemt−/−mice fed the high-fat diet,
but rather the deﬁciency in choline biosynthesis provided the beneﬁcial
effect. Further evidence for this hypothesiswas obtainedwhen Pemt+/+
mice were fed the choline-deﬁcient diet for 12 weeks; thesemice were
also protected from diet-induced obesity/insulin resistance [66]. These
observations are consistent with the report that when obese mice
were fed either a choline-deﬁcient, or a choline-supplemented/high
fat diet, for 4 weeks insulin resistancewas lower in the choline deﬁcient
mice [69]. During this period no difference was observed inweight gain
betweenmice fed the two diets [69]. Moreover, when male ob/ob mice
(lack leptin and become very obese) were fed a high fat diet±choline
for two months, the choline deﬁcient mice gained less weight andexhibited improved insulin and glucose tolerance compared to the
choline-supplemented mice [70].
How does a decreased supply of choline produce an anti-obesity/
anti-insulin resistance phenotype in mice?While current data strong-
ly suggest that the liver is involved in determining the phenotype, re-
cent studies with 3T3-L1 adipocytes suggest that PEMT in adipose
tissue might also be involved [19]. PEMT is not expressed in 3T3-L1
ﬁbroblasts but 4 days after the cells are differentiated into adipocytes,
PEMT is expressed. Subsequent experiments demonstrated that PEMT
had an important role in the stabilization of lipid droplets in 3T3-L1
adipocytes [19]. Hence, although the activity of PEMT is relatively
low in adipose tissue compared to liver, the conversion of PE to PC ap-
pears to be important for normal fat deposition. Thus, lack of PEMT in
adipose tissue might contribute to the lower fat mass in mice fed the
high-fat diet for 10 weeks.
9. The human connection
With the progress in DNA sequencing it is now possible to gain in-
sight into human physiology through studies on genetic polymorphisms.
Thus, Zeisel and co-workers found that a Val-to-Met substitution at res-
idue 175 of the human PEMT protein was associated with non-alcoholic
fatty liver disease in a group composedmainly of Caucasians [71]. cDNAs
encoding the Val isoform and the Met form of PEMT were expressed in
McArdle hepatoma cells and the Met isoform of PEMT had ~40% lower
speciﬁc activity than the Val form [71]. When the polymorphism for res-
idue 175 was examined in 59 control subjects and 28 humans with
nonalcoholic liver disease, the Met/Met substitution occurred in 68% of
the subjects with non-alcoholic liver disease but in only 41% of control
subjects. Thus, the V175M polymorphism was suggested to confer sus-
ceptibility to nonalcoholic liver disease in humans. In agreement with
this conclusion, the V175M variant was found to bemore frequent in pa-
tients with non-alcoholic steatohepatitis than in healthy subjects [72]. In
contrast, no association between the V175Mmutation and steatosis was
observed in the Dallas Heart study that involved multiple races [73].
When only Caucasians were considered in the Dallas Heart study a rela-
tionship between the V175M polymorphism and liver disease became
apparent [74]. Thus, it appears that Caucasians have a different distribu-
tion of this polymorphism than Hispanics and African Americans. Zeisel
also suggests that the V175M polymorphism may be associated with
fatty liver only if the secretion of TG into VLDL is decreased and/or TG
synthesis increased [74].
A single nucleotide polymorphism (G to C)was also identiﬁed in the
promoter region of the PEMT gene [75]. Of the 23 subjects that had the C
allele, 18 developed “organ dysfunction” when fed a low choline diet.
Subsequently, a dose–response relationship also was revealed between
the C allele and organ dysfunction in subjects fed a very-low-choline
diet. In pre-menopausal women, those with 2 C alleles were much
more likely to develop organ problems than were women with 1 or
0 C alleles [76]. Post-menopausal women who received estrogen were
much less likely to develop organ dysfunction when fed a low choline
diet [76]. The authors concluded that post-menopausal women with
low estrogen levels have a higher dietary requirement for choline
than do pre-menopausal women. Moreover, the C allele increased the
requirement for choline in both groups of women [76].
10. Future directions
Fig. 5 provides a summary of the different functions of PEMT in
mouse liver. Although there has been signiﬁcant progress in under-
standing the roles of PEMT in the past two decades, there are still
many important questions to be addressed. Of key importance is to
determine the mechanism(s) by which large supplements of choline
can override the protection from obesity/insulin resistance observed
in Pemt−/−mice fed a high fat diet. Second, pharmaceutical inhibition
of PEMTmight protect humans from atherosclerosis, obesity and type
PE + 3 AdoMet 
Bile PC + 3 AdoHcy 3 HCY
Choline
VLDL Membranes 
TG
?
PEMT
Fig. 5. Physiological roles for PEMT in mouse liver. Phosphatidylethanolamine (PE)+3
S-adenosylmethionines (AdoMet) is converted to phosphatidylcholine (PC) and 3
S-adenosylhomocysteines (AdoHcy) by PEMT. PC is utilized for: the structure of all
membranes in the hepatocye, the formation of choline, secretion of very low density
lipoproteins (VLDL), secretion into bile and possibly the formation of triacylglycerols
(TG). AdoHcy is converted to homocysteine (Hcy) that is secreted into the plasma.
631D.E. Vance / Biochimica et Biophysica Acta 1831 (2013) 626–6322 diabetes, although a complication is the development of steatosis/
steatohepatitis in Pemt−/− mice fed the high fat diet. Thus, it impor-
tant to determine if steatosis also occurs in animal models, such as
the guinea pig or hamster, that have a lipid metabolic proﬁle closer
to that in humans. If steatosis also occurred in these animals, one
would need to think creatively about mechanisms by which steatosis
might be relieved when PEMT was inhibited. A third consideration is
that PC in hepatocyes [77], and PC associated with low density lipo-
proteins [78] and high density lipoproteins [79,80] that are supplied
to hepatocytes, is a source of signiﬁcant amounts of TG. It is not yet
known if PC made via PEMT is an important source of hepatic TG.
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